Onkologie. 2021:15(6):272-276 | DOI: 10.36290/xon.2021.051

Treatment options for non-small cell lung stage III cancer

Martin Svatoň1, Daniel Krejčí2
1 Klinika pneumologie a ftizeologie, Univerzita Karlova, Lékařská fakulta v Plzni
2 Klinika pneumologie, 3. LF UK, Praha

This work deals with a wide range of treatment options for patients with stage III non-small cell lung cancer (NSCLC). The article discusses the possibilities of surgical solutions, where it points to the irreplaceable role of a multidisciplinary team, especially in patients with positive lymph nodes of category N2. In this part, the possibilities of neoadjuvant/adjuvant chemotherapy or immunotherapy are also discussed. The issue of postoperative radiotherapy is also discussed. In patients who are not suitable for resection, the work deals with the reasons for the preference for concomitant over sequential chemoradiotherapy. Furthermore, the article discusses the addition of durvalumab as a consolidation therapy and some issues related to immunotherapy in this context. The last part is devoted to targeted treatment in patients with stage III NSCLC, especially the study with adjuvant administration of osimertinib.

Keywords: NSCLC, stage III, chemotherapy, immunotherapy, radiotherapy.

Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svatoň M, Krejčí D. Treatment options for non-small cell lung stage III cancer. Onkologie. 2021;15(6):272-276. doi: 10.36290/xon.2021.051.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest 2017; 151(1): 193-203. Go to original source... Go to PubMed...
    2. Jazieh AR, Zeitouni M, Alghamdi M, et al. Management guidelines for stage III non-small cell lung cancer. Crit Rev Oncol Hematol 2021; 157: 103144. Go to original source... Go to PubMed...
    3. Myall NJ, Das M. Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. Clin Chest Med 2020; 41(2): 211-222. Go to original source... Go to PubMed...
    4. Van Meerbeeck JP, De Pooter C, Raskin J, et al. Local treatment of stage IIIA-N2 nonsmall cell lung cancer: surgery and/or radiotherapy. Curr Opin Oncol 2020; 32(1): 54-62. Go to original source... Go to PubMed...
    5. Palmero R, Vilariño N, Navarro-Martín A, et al. Induction treatment in patients with stage III non-small cell lung cancer. Transl Lung Cancer Res 2021; 10(1): 539-554. Go to original source... Go to PubMed...
    6. Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res 2020; 6(1). Go to original source... Go to PubMed...
    7. Yamaguchi M, Nakagawa K, Suzuki K, et al. Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. Jpn J Clin Oncol 2021; 51(3): 333-344. Go to original source... Go to PubMed...
    8. Gentzler RD, Riley DO, Martin LW. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. Curr Oncol Rep 2020; 22(11): 109. Go to original source... Go to PubMed...
    9. Ahern E, Solomon BJ, Hui R, et al. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? J Immunother Cancer 2021; 9(6). Go to original source... Go to PubMed...
    10. Pechoux C. LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Annals of Oncology 2020; 31(Suppl_4): S1142-S1215. Go to original source...
    11. Hui Z, Men Y, Hu C, et al. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy. JAMA Oncology 2021. Go to original source...
    12. Verma V, Lin SH. Optimizing current standard of care therapy for stage III non-small cell lung cancer. Transl Lung Cancer Res 2020; 9(5): 2033-2039. Go to original source... Go to PubMed...
    13. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 2021; 39(15_suppl): 8500-8500. Go to original source...
    14. Conibear J. Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer. Br J Cancer 2020; 123 (Suppl 1): 10-17. Go to original source... Go to PubMed...
    15. Storey CL, Hanna GG, Greystoke A. Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer. Br J Cancer 2020; 123(Suppl 1): 28-35. Go to original source... Go to PubMed...
    16. Puri S, Saltos A, Perez B, et al. Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep 2020; 22(4): 31. Go to original source... Go to PubMed...
    17. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377(20): 1919-1929. Go to original source... Go to PubMed...
    18. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018; 379(24): 2342-2350. Go to original source... Go to PubMed...
    19. Gray JE, Villegas A, Daniel D, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol 2020; 15(2): 288-293. Go to original source... Go to PubMed...
    20. Mielgo-Rubio X, Rojo F, Mezquita-Pérez L, et al. Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World J Clin Oncol 2020; 11(11): 898-917. Go to original source... Go to PubMed...
    21. Käsmann L, Eze C, Taugner J, et al. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 2020; 15(1): 167. Go to original source... Go to PubMed...
    22. Jabbour SK, Berman AT, Decker RH, et al. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol 2020; 6(6): 848-855. Go to original source... Go to PubMed...
    23. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383(18): 1711-1723. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.